TD Asset Management
FATE icon

TD Asset Management’s Fate Therapeutics FATE Stock Holding History

TD Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$184K – 1383
2024
Q1 		$184K Buy
+25,000
New +$155K ﹤0.01% 1360
2023
Q4 		– Sell
-141,652
Closed -$300K – 1414
2023
Q3 		$300K Buy
141,652
+70,826
+100% +$235K ﹤0.01% 1340
2023
Q2 		$337K Hold
70,826
– – ﹤0.01% 1323
2023
Q1 		$404K Hold
70,826
– – ﹤0.01% 1304
2022
Q4 		$715K Sell
70,826
-18,700
-21% -$351K ﹤0.01% 1208
2022
Q3 		$2M Sell
89,526
-22,714
-20% -$656K ﹤0.01% 1002
2022
Q2 		$2.78M Sell
112,240
-5,340
-5% -$147K ﹤0.01% 908
2022
Q1 		$4.56M Buy
117,580
+10,899
+10% +$422K ﹤0.01% 843
2021
Q4 		$6.24M Hold
106,681
– – 0.01% 807
2021
Q3 		$6.32M Buy
106,681
+18,871
+21% +$1.48M 0.01% 764
2021
Q2 		$7.27M Sell
87,810
-800
-0.9% -$64.5K 0.01% 738
2021
Q1 		$7.31M Sell
88,610
-570
-0.6% -$54.6K 0.01% 724
2020
Q4 		$8.11M Buy
89,180
+30,700
+52% +$1.91M 0.01% 652
2020
Q3 		$2.34M Buy
58,480
+24,100
+70% +$841K ﹤0.01% 870
2020
Q2 		$1.18M Buy
34,380
+3,271
+11% +$97.5K ﹤0.01% 1017
2020
Q1 		$691K Sell
31,109
-3,900
-11% -$98.6K ﹤0.01% 1100
2019
Q4 		$685K Sell
35,009
-7,100
-17% -$113K ﹤0.01% 1186
2019
Q3 		$654K Buy
42,109
+200
+0.5% +$3.83K ﹤0.01% 1137
2019
Q2 		$851K Buy
41,909
+1,700
+4% +$30.6K ﹤0.01% 1079
2019
Q1 		$706K Sell
40,209
-4,000
-9% -$63.1K ﹤0.01% 1107
2018
Q4 		$567K Buy
44,209
+3,024
+7% +$42.2K ﹤0.01% 1195
2018
Q3 		$671K Buy
41,185
+5,785
+16% +$68.4K ﹤0.01% 1235
2018
Q2 		$401K Sell
35,400
-6,200
-15% -$68.3K ﹤0.01% 1308
2018
Q1 		$406K Buy
41,600
+22,932
+123% +$220K ﹤0.01% 1237
2017
Q4 		$114K Buy
+18,668
New +$83.3K ﹤0.01% 1322

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TD Asset Management's FATE Position: Q2 2024 in Review

TD Asset Management sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 25,000 shares — an estimated $184K sold.

TD Asset Management first reported a position in FATE in Q4 2017 and held it in 25 quarters. The position peaked at $8.11M in Q4 2020. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • TD Asset Management reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • TD Asset Management sold 25,000 Fate Therapeutics shares in Q2 2024, an estimated $184K.
  • TD Asset Management first reported a position in Fate Therapeutics in Q4 2017 and held it in 25 quarters.
  • TD Asset Management's Fate Therapeutics position peaked at $8.11M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on TD Asset Management's 13F filing for Q2 2024, filed 2 Aug 2024.